Multicentric Phase II Trial to Evaluate the Efficacy and Safety of Ibrutinib in Combination With Rituximab in Patients With Indolent Clinical Forms of Mantle Cell Lymphoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 28 Feb 2024

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

23 Feb 2024 Planned End Date changed from 1 Jan 2023 to 1 Dec 2024.
14 Jan 2022 An amendment was made which allowed accepting a response evaluation at 6 months instead of 12 months, by using CT scan and BM aspirate, to avoid excessive recruitment time as per results published in the Journal of Clinical Oncology
14 Jan 2022 Primary endpoint (Rate of complete remission) has been met as per results published in the Journal of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com